

Europe's definitive event for obesity and diabetes drug development

Register before 13 September and save up to £269.67!

Obesity Drug Development World 2007

26 – 28 November 2007, Millennium Hotel London Mayfair, London, UK

“ Obesity is one of the major health problems of our present time. Finding drug treatments that are effective and safe has proved immensely difficult. This conference brings together a range of molecular targets each championed by the drug discovery leaders of the day and presents a rare opportunity to gain a full picture of the drug discovery and development scene. ”

Professor Michael Cawthorne,
Director of Metabolic Research and Professional Research Fellow,
University of Buckingham

“ Despite the significant unmet medical need of obesity, developing effective and safe therapies remains an arduous process. By covering the scientific, regulatory, and commercial aspects of obesity drug development, *Obesity Drug Development World* provides a valuable forum to better understand both the challenges and opportunities in this therapeutic area. ”

Dr Hubert Chen,
Director of Clinical Research,
Amylin Pharmaceuticals



New dimensions.

Key speakers include:



Dr Douglas Greene
Senior Vice President and Chief Medical Officer
sanofi aventis



Dr Alan Harris
Chief Medical Officer
Manhattan Pharmaceuticals



Dr Matthew Coghlan
Candidate Drug Delivery Team Leader, Diabetes and Drug Discovery
AstraZeneca



Dr Gordon Brandt
Executive Vice President of Clinical Research and Medical Affairs
Nastech Pharmaceuticals



Dr Ann Taylor
Director and Clinical Lead for Early Obesity Development
Pfizer Global R&D



Dr Michael Hayden
Chief Scientific Officer
Xenon Pharmaceuticals



Dr Nir Barak
Chief Scientific Officer
OBEcure



Dr Eduardo Dunayevich
Chief Medical Officer
Orexigen Therapeutics



Dr Michael Trautmann
Medical Fellow, BYETTA Global Brand Team
Lilly Deutschland

Lean investment. Large returns.

- Metabolic research and development strategies based on unmet market needs
- Scientific and commercial analysis of key anti-obesity and diabetic compounds
- Case studies on clinical trial endpoints and late-stage candidate drug development
- Key factors contributing to the success of next generation anti-obesity and metabolic drugs
- Gain new business partnerships with pre-qualified companies through structured networking opportunities

Partners

Organised by

COVANCE

O.M.A
Obesity Management Association



terrapiinn
B2B media

New dimensions.

Revolutionising drug discovery and development

Advance your obesity and metabolic drug discovery strategy at *Obesity Drug Development World 2007*

Obesity has become a significant global problem particularly in the younger generation. The increasing incidence of obesity is having a huge impact on the state of human health, not only creating obvious problems with mobility, but also consequences in the wider context of type II diabetes, cardiovascular disease, stroke and cancer related conditions.

As new targets, pathways and strategies to enhance drug development come to light, the race is on to develop therapies with novel mechanisms that can be used to treat obesity and its wider implications. The reality of these new ideas will soon become visible as a new wave of key Phase II trials near their completion. What we are presently seeing is a cohort of obesity players reaching late stage development with improved, revived and repurposed approaches.

However, despite the number of investigational and approved therapies currently increasing, inherent problems exist in moving these drugs from the clinical development stage to market.

Obesity Drug Development World is this year's leading European event for the obesity and drug development market to meet with industry peers, identify new targets, pathways and mechanisms and further your understanding of obesity and diabetes drugs in clinical development. The conference will enable you to relate to key drugs and compounds in various clinical phases and develop your understanding of the latest scientific techniques and business strategies that will take your own research to the next level.



Why wait? Book your place today for all 3 days to gain the greatest insight into obesity and metabolic drug development

Fax the registration page to +44 (0) 207 242 2320
or register online at www.lifescienceworld.com/2007/obesity

Scientific advisory board



Professor Michael Cawthorne
Director of Metabolic Research
and Professorial Research Fellow
University of Buckingham

Professor Cawthorne leads a group of 15 researchers seeking new molecular targets and evaluating pioneering therapies for obesity and type II diabetes. He has published more than 100 papers in peer-reviewed journals, is a past Chairman of the Association for the Study of Obesity, was founding secretary of the International Association for the Study of Obesity and received the 2001 award for drug discovery from the Society of Medicines Research.



Dr Itzik Harosh
Chairman and
Chief Scientific Officer
ObeTherapy

Dr Harosh, founder of the company, is the inventor of both patents now owned by the company and has a well-established international reputation. Dr Harosh has wide experience in drug discovery vision, target identification and validation, assay developments adaptable for HTS, secondary screenings and animal model. In addition, he has in depth knowledge of biochemistry and molecular biology.



Professor David Heal
Director, **RenaSci Consultancy** and
Visiting Professor, Department of
Pharmacy and Pharmacology
University of Bath

Professor Heal transferred to pharmaceutical research and development in the mid 1980's. Whilst in pharmaceutical research and development, he led teams which put several novel drugs, including the anti-obesity drug, sibutramine, through clinical development. In 2001, he co-founded RenaSci Consultancy Ltd, where he is currently a Board Director. RenaSci is an independent provider of consultancy and experimental services to the pharmaceutical industry in the therapeutic areas of obesity, diabetes and CNS disorders.



Professor Jonathan Arch
Deputy Director of Metabolic
Research, Clore Laboratory
University of Buckingham

Professor Arch was formerly a director in a drug discovery department of SmithKline Beecham (now GlaxoSmithKline) and he retains contact with the pharmaceutical industry. He has published over 100 peer-reviewed papers, reviews and book chapters and regularly addresses scientific meetings.

“ The identification and development of drugs that not only produce good weight loss but can safely be given for long periods to a significant proportion of the population presents a major challenge to the pharmaceutical industry. *Obesity Drug Development World* is structured to give participants both detail and perspective on opportunities and risks in this area. ”

Professor Jonathan Arch,
Deputy Director of Metabolic Research,
Clore Laboratory,
University of Buckingham

The Terrapin

- Real case studies presented by CxO's
- Powerpoint actively discouraged. Interaction encouraged
- Q&A sessions a formal part of the proceedings
- Panel sessions creating a talk show rather than a lecture
- Buffet lunches that encourage networking
- Drinks receptions to network and relax

ment for obesity and metabolic syndrome



“ Although global obesity is at epidemic proportions, the route to the approval of new drugs is extremely difficult and major commercial success for anti-obesity agents remains elusive. In this challenging arena, *Obesity Drug Development World* provides a timely opportunity to take stock of the situation aided by some of the world's leading experts in the field. ”

Professor David Heal, Director, RenaSci Consultancy and Visiting Professor, Department of Pharmacy and Pharmacology, University of Bath

n difference



- Speed networking increasing the number of people you meet
- Contact: facilitating networking before, during and after the event
- A year long, extensive marketing campaign
- Real value for sponsors, speakers and exhibitors

A Terrapinn event is an experience.

Pre-conference briefing Monday 26 November 2007

BRINGING THERAPIES FOR TYPE II DIABETES CLOSER TO MARKET

- 09.00 Chairman's opening remarks**
Pierre Honoré, Vice President, Strategy and Sourcing, Diabetes Research, **Novo Nordisk**

METABOLIC MILESTONES – NEW TARGETS, MECHANISMS AND THERAPIES

- 09.10 Type II diabetes therapeutic development accompanying obesity therapies**
- Drug development and strategies to expand pipeline diversity and metabolic focus
- Pierre Honoré**, Vice President, Strategy and Sourcing, Diabetes Research, **Novo Nordisk**
- 09.30 Underscoring the need for new therapies with new mechanisms**
- Druggable targets and providing proof-of-concept for a number of mechanisms
- Dr Håkan Wennbo**, Vice President Portfolio Strategy - Diabetes and Obesity, **AstraZeneca R&D**

IDENTIFYING DRUGGABLE TARGETS

- 10.00 Targeting the sodium glucose transporter 2 inhibitor**
- SGLT2 inhibitor working in combination with existing drugs
- Dr Chari Smith**, Section Manager Biochemistry Metabolic CEDD, **GlaxoSmithKline**
- 10.30 Morning coffee**
- 11.00 Revealing an uncommon approach to targeting glucokinase activators**
- GKA acting as allosteric activators and the effectiveness of glucokinase enzymes
- Dr Matthew Coghlan**, Candidate Drug Delivery Team Leader, Diabetes and Drug Discovery, **AstraZeneca**
- 11.30 Inhibiting 11beta-hydroxysteroid dehydrogenase type 1**
- 11 β HSD1 as a druggable target and catalysing the conversion of cortisone to cortisol
- Dr Reid Huber**, Senior Director, Metabolic Endocrine Drug Development, **Incyte**
- 12.00 Current clinical development of gastro intestinal hormones as treatments for diabetes: GLP-1 receptor agonists and Exenatide**
- Approaches for using the incretin system through GLP-1 receptor agonists
- Dr Michael Trautmann**, Medical Fellow, BYETTA (Exenatide) Global Brand Team, **Lilly Deutschland**
- 12.30 Lunch**
- 14.00 Current development of long-acting GLP-1 analogs and Liraglutide**
- Overview of clinical efficiency in the GLP-1 related drug classes
- Dr Peter Kristensen**, Corporate Vice President, Liraglutide, **Novo Nordisk**
- 14.30 Insulin sensitising agent for the treatment of type II diabetes**
- Nitric-oxide releasing therapeutics for the treatment of diabetes
- Dr Staffan Stromberg**, Director of Drug Development, **NicOx**
- 15.00 GPR119 agonists as potential agents for the treatment of "diabesity"**
- Studies describing the effects of these GPR119 agonists in various cell models and animal models of obesity and diabetes
- Dr Jim McCormack**, Vice President Research and Chief Scientific Officer, **Prosidion Ltd. (a subsidiary of OSI Pharmaceuticals Inc.)**
- 15.30 Afternoon tea**
- 16.00 Fighting type II diabetes with 'expenditure genes'**
- A new approach for identifying genes for diabetes treatment
- Dr Itzik Harosh**, Chairman and Chief Scientific Officer, **ObeTherapy**

COMBINATION PHARMACOTHERAPY

- 16.30 Challenges and opportunities for the development of combination drug therapies**
- Outlining important new drug combination therapies for various metabolic disorders
- Dr Uwe Gudat**, Global Brand Medical Director, Dyslipidemia and Diabetes, **Novartis**
- 17.00 Close of pre-conference briefing**

Accelerating drug discovery and development

Day one Tuesday 27 November 2007

09.00 Chairman's opening remarks
Professor Michael Cawthorne, Director of Metabolic Research and Professorial Research Fellow, **University of Buckingham**

ANTI-OBESITY MARKET AND PRODUCT ADVANCEMENT

09.10 Keynote presentation: evaluating the defining opportunities in obesity drug development

- Changing dynamics of obesity drug development
- Who is succeeding and how? Developers and manufacturers navigating the arena
- Lessons learned; key barriers today and in the near future

Professor Michael Cawthorne, Director of Metabolic Research and Professorial Research Fellow, **University of Buckingham**

09.40 Increased efficacy with rimonabant: evaluating the novel approach with cannabinoid 1 receptor

- CB1 signaling linked to nicotinic, dopaminergic and other important pathways
- Current programmatic and clinical developments with Acomplia™
- What next? What does the future hold for drug development?

Dr Antonio Tataranni, Vice President, Metabolism MU, **sanofi aventis**

10.10 Morning coffee

IMPROVED DRUG DEVELOPMENT USING EXISTING TARGETS AND MECHANISMS

10.40 Forthcoming cannabinoid-1 receptor blockers

- Current wave of small molecule antagonising CB1 receptors
- Current pre-clinical and clinical developments

Moderator:

Professor Michael Cawthorne, Director of Metabolic Research and Professorial Research Fellow, **University of Buckingham**

Panellists:

Dr Antonio Tataranni, Vice President, Metabolism MU, **sanofi aventis**

Dr Tung Fong, Director, Metabolic Disorders,

Merck Research Laboratories

Dr Shridhar Narayanan, Vice President Biological Research, **Glenmark Pharmaceuticals**

Dr Guy Kennett, Senior Fellow Researcher, **Vernalis**

11.40 Future prospects for serotonergic drugs in the treatment of obesity and related metabolic disorders

- The renaissance of pharmaceutical interest in serotonergic approaches to the treatment of obesity
- Developing both 5-HT_{2C} agonists and 5-HT₆ agonists
- Reviewing the regulatory challenges facing these drugs and their potential for commercial success

Professor David Heal, Director, **RenaSci Consultancy** and Visiting Professor, Department of Pharmacy and Pharmacology, **University of Bath**

12.10 Speed Networking

13.00 Lunch

14.00 Key strategies for effective drug discovery

- Discovering the multitude of potential drug targets for obesity
- Problems inherent in both investigational and approved anti-obesity therapies
- Enhancing therapeutic potential of novel anti-obesity drugs

Professor Jonathan Arch, Deputy Director of Metabolic Research, Clore Laboratory, **University of Buckingham**

14.30 Fostering regulatory approval for furthering obesity drug research and development

- Current guidelines placed on regulating obesity drugs
- Pathways for accelerated compound / product approval
- Efficacy and safety during the regulatory approval process

Dr Douglas Greene, Senior Vice President and Chief Medical Officer, **sanofi aventis**

PRE-CLINICAL AND ANIMAL MODELLING FOR OBESITY STUDIES

15.00 Animal models in obesity studies and the improvement of existing therapies

- Optimising the choice of models for each development stage
- Animal models currently in use for evaluation of therapeutic efficacy and safety of anti-obesity molecules
- Application of rodent findings to large animal studies

Dr Marcus Schindler, Associate Director, Metabolic Diseases Research, **Boehringer Ingelheim**

15.30 Afternoon tea

16.00 Animal models for pre-clinical testing of drug candidates

- Rodent models for predicting clinical efficacy of new compounds
- Obesity related cardio-metabolic risk factors modelled in rodents
- Validity of rodent models for predicting weight-loss efficacy

Dr David Morgan, Team Leader, **AstraZeneca R&D**

16.30 Panel session: linking animal measurements to phase I / IIa

- Animal models linking to measurements that can be made in Phase I / IIa
- Future for Phase I / IIa studies with obesity drug development

Moderator:

Professor Michael Cawthorne, Director of Metabolic Research and Professorial Research Fellow, **University of Buckingham**

Panellists:

Dr Marcus Schindler, Associate Director, Metabolic Diseases Research, **Boehringer Ingelheim**

Dr David Morgan, Team Leader, **AstraZeneca R&D**

Professor David Heal, Director, **RenaSci Consultancy** and Visiting Professor, Department of Pharmacy and Pharmacology, **University of Bath**

DEVELOPMENT OF BIOMARKERS AND DIAGNOSTIC TOOLS

17.00 Confirming the presumed mechanism of action using obesity biomarkers

- Optimal biomarkers; diagnostic criteria for cardiovascular diseases to identify early pathologic processes
- Obesity biomarkers used to confirm the presumed mechanism of action
- The need for further validation of biomarkers

Dr Ann Taylor, Director and Clinical Lead for Obesity Early Development, **Pfizer Global R&D**

17.30 Close of day one followed by networking drinks

Networking drinks reception



There are over 10 hours of dedicated networking time at *Obesity Drug Development World*. The highlight being the drinks reception at the end of day one. A great way to extend your networking in a relaxed and entertaining environment. Register online at www.lifescienceworld.com/2007/obesity

for obesity, diabetes and metabolic syndrome

Day two Wednesday 28 November 2007

09.00 Chairman's opening remarks

Professor David Heal, Director, **RenaSci Consultancy** and Visiting Professor, Department of Pharmacy and Pharmacology, **University of Bath**

CNS TARGETS AND OBESITY DRUG DEVELOPMENT

09.10 A sustained-release combination of bupropion, a dual dopamine and norepinephrine reuptake inhibitor

- **Contrave™** – understanding of the central nervous system
- Activating central pathways associated with both a reduction in appetite and an increase in the expenditure of energy
- Longer term efficacy of combining bupropion with naltrexone

Dr Eduardo Dunayevich, Chief Medical Officer, **Orexigen Therapeutics**

09.40 Anti-obesity compounds comprising betahistine

- Histamine analog agonising histamine H1 receptors and partially agonising H3 receptors
- Side-stepping the side effects encountered by pharmaceutical companies when pursuing novel small molecule H3 antagonists
- Future trials looking into metabolic markers; plasma lipids, LDL, HDL

Dr Nir Barak, Chief Scientific Officer, **OBEcure**

10.10 Taking a re-profiling approach with a CNS directed agent

- Tesofensine's mixed mechanism
- The triple serotonin, dopamine and noradrenaline reuptake inhibitor proof of safety
- Avoiding mood disorders based on its antidepressant-like serotonin reuptake activity

Dr Dieter Meier, Executive Vice President and Chief Medical Officer, **NeuroSearch**

10.40 Morning coffee

11.10 Qnexa™ – combination therapy for weight loss and obesity-related co-morbidities

- Rationale for combination therapy in the treatment of obesity-related metabolic disorders
- Complementary pharmacology for both safety and efficacy
- Clinical experience with Qnexa™ to date

Dr Wesley Day, Vice President, Clinical Development, **VIVUS**

DUAL ACTING ANTI-OBESITY AGENTS

11.40 Developing a synthetic version of oleoyl-estrone, and endogenous hormone produced in white adipose tissue

- Oleoyl-estrone targeting the brain and functioning peripherally
- Phase IIa studies to evaluate key therapeutic outcomes
- Target validation, design, dosing and duration of Phase IIb trials

Dr Alan Harris, Chief Medical Officer, **Manhattan Pharmaceuticals**

GUT HORMONES AS ANTI-OBESITY TARGETS

12.10 Novel approach in harnessing additive / synergistic effects of adipocyte, islet and gut derived hormones

- Neurohormonal approach for the treatment of obesity
- Role of neurohormones in the regulation of food intake and energy expenditure
- Clinical results with pramlintide, an amylin agonist plus preclinical results with amylin, PYY3-36, and leptin

Dr Hubert Chen, Director of Clinical Research, **Amylin Pharmaceuticals**

12.40 Lunch

14.00 Evaluating the potential of PYY as an appetite suppressant

- PYY3-36 and Y2 receptors believed to play a role in inducing satiety

- Is the PYY3-36 mechanism a candidate for a combination approach?

- Translating current results - ongoing Phase II

Dr Gordon Brandt, Executive Vice President Clinical Research and Medical Affairs, **Nastech Pharmaceuticals**

14.30 Agonising Y2 and Y4 receptors with TM30338 synthetic peptide analog

- PYY3-36 and pancreatic polypeptides to address the Y4 receptor
- Advantages of hitting two satiety signals at the same time
- Phase II trials further qualifying the pathway and target as well as the pharmacology of the target

Dr Christian Elling, Director of Molecular Pharmacology and Development, **7TM Pharma**

PERIPHERALLY ACTING ANTI-OBESITY AGENTS

15.00 A dual-mechanism approach to inhibiting anti-obesity drug targets

- Increasing metabolism without a concomitant increase in appetite
- Increasing the activity of the lipase enzyme implicated in the transport and metabolism of triglycerides
- Viability of targeting both the adipose triglyceride lipase pathway as well as phosphoinositide 3-kinase

Dr Nigel Levens, Chief Scientific Officer, **Innodia**

15.30 Afternoon tea

ENZYMES AS DRUG TARGETS

16.00 Researching, developing and commercialising compounds from stearoyl-CoA desaturase-1 (SCD1)

- Pursuing rapid validation of SCD1 as a relevant therapeutic target
- SCD1 enzyme showing promise as a key regulator of fatty acid metabolism and insulin action
- Developing small molecule inhibitors of SCD1 and advanced pre-clinical development

Dr Michael Hayden, Chief Scientific Officer, **Xenon Pharmaceuticals**

16.30 Panel session: pros and cons of brain receptors, gut hormones and peripheral targets

- Attractiveness of each individual target
- What is working and what is not. Is there a need for novel approaches?

Moderator:

Professor David Heal, Director, **RenaSci Consultancy** and Visiting Professor, Department of Pharmacy and Pharmacology, **University of Bath**

Panellists:

Dr Eduardo Dunayevich, Chief Medical Officer, **Orexigen Therapeutics**

Dr Gordon Brandt, Executive Vice President of Clinical Research and Medical Affairs, **Nastech Pharmaceuticals**

Dr Nigel Levens, Chief Scientific Officer, **Innodia**

17.00 Close of conference

Don't miss this opportunity to meet the key anti-obesity and diabetes industry figures.

Fax the registration page to +44 (0) 207 242 2320 or register online at www.lifescienceworld.com/2007/obesity

New dimensions.

More hours of dedicated networking than any other obesity and diabetes drug development event

contact Introducing you to your customers, your peers and your suppliers. 'Contact' is Terrapinn's unique online introductory service. It's a simple system designed with event attendees in mind, giving you the list of attendees and the option to email them. It is available to all event attendees. Don't leave meeting the best event attendees to chance. Contact them before and after the event.



SPEED NETWORKING This is the revolutionary, exciting and non-pressured way to meet fellow conference attendees and industry peers in a 50 minute session. It is a part of the formal conference agenda. These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and profitable business relationships begin. **Make sure you bring lots of business cards!**



PANEL SESSION The conference programme includes several panel sessions. These are chat show style sessions creating an interactive environment rather than a lecture. The panellists are chosen for their views and lively debate is encouraged. This is your chance to interact and put your questions to the panel.



This networking drinks reception is a great opportunity to meet other attendees after the conference day ends. Held at the end of the first main conference day, this is your perfect opportunity to network with your peers in an informal setting. This is a relaxed, informal and entertaining event.

The venue



Situated in the heart of the fashionable Mayfair neighbourhood, seconds walk to Park Lane, Bond Street, Hyde Park and Oxford Street, a magnificent 18th Century mansion first built as a stately town house.

Overlooking the lush Grosvenor Square, the 4 star deluxe Millennium Hotel London Mayfair, with its Georgian facade has all the discreet charm of an exclusive private residence. A short walk from Bond Street and Green Park underground stations, London's main attractions and amenities are within easy reach, including the shops and boutiques of Oxford Street and Bond Street, theatre land and the City's financial centres. The wide-open spaces of Hyde Park and Kensington gardens are nearby offering relaxation.
www.millenniumhotels.com

Commercialising obesity and at the premier obesity event

Take advantage of the predicted growth in the future of the obesity market

- Q1:** Do you target decision makers from pharmaceutical and biotech companies in the obesity industry?
- Q2:** Can you provide a solution to some of the challenges that obesity and diabetes drug development companies are facing?
- Q3:** Can you show our delegates how to advance their drug development?
- Q4:** Can you share your industry expertise with leaders from the pharmaceutical and biotech sectors?

If so, don't miss out on meeting your target market at *Obesity Drug Development World 2007*.

Obesity Drug Development World 2007 will cover the key commercial challenges in obesity and diabetes drug development, which take account of new therapeutic targets, bringing therapies closer to market, overcoming inactivity on the part of pharmaceutical companies, product advancement, pre-clinical and clinical trials.

Terrapinn has been running life science conferences like the *World Vaccine Congress* and *bioLOGIC* series successfully for 9 years. Drawing from our experience and expertise gained over the years, we have created an event which focuses on the commercial challenges and issues faced in obesity and diabetes drug development, in close conjunction with industry specialists from the pharmaceutical and biotech sectors.



Meet your target audience during the extended networking breaks

“ Great networking due to organisation of the conference. ”

Stacey Vaughan, Director,
Business Development, **Cardinal Health**
(Said of *World Vaccine Congress Washington 2007*)


“ High quality presentations, good networking opportunities – speed networking excellent, number of participants very good, also the spread between companies. ”

Catharina Hemstrom,
Product Manager, **GE Healthcare**
(Said of the *European BioPharm Scale-Up Congress 2006*)

diabetes drug development strategies – find new partners in 2007

Reap the benefits from the high value buyers and decision makers in your industry


Obesity Drug Development World 2007 is your chance to benefit from a globally integrated and cost effective sales and marketing solution for the obesity and diabetes industry. This 6 month campaign culminates in a conference which gives you face-to-face time with your prospective and existing clients.



Remember to bring plenty of business cards!

Meet the people that matter

Take a look at who attends our typical events so you can be sure that you will **meet the people that matter** to your business and leverage the highest return possible from your marketing budget.



Get your message across to the obesity and diabetes market! Contact Ince Saleem on +44 (0) 207 092 1323 or email ince.saleem@terrapinn.com to see how we can help you!

Improve the likelihood of being the logical supplier of choice

Obesity Drug Development World 2007 is the place where strategy, know how and ideas come together. By being part of the event, you will have the opportunity to shape this leading conference and influence industry direction. If you are not there, your voice and services will not be heard.

We can help you to:

- Raise your companies profile to make you the logical choice of supplier
- Get your message in front of the real decision makers in the industry
- Market directly to your top 10 wish list!
- Meet your clients and build your sales pipeline

Show your prospective customers how you can excel their needs and significantly increase your chances of being selected as a partner.

Event exhibitor



Event and media partners



Response form Fax Back to +44 (0) 207 242 4303

Yes! I am interested in sponsorship opportunities. Please contact me immediately

Yes! I am interested in exhibiting. Please contact me immediately

Name:

Job title:

Company:

Address:

Postcode:

Country:

Tel:

Fax:

Email:

Event code:14/1327

Registration form

Obesity Drug Development World 2007

26 – 28 November 2007, London, UK

5 easy ways to register

Phone: +44 (0) 207 242 2324
Fax: +44 (0) 207 242 2320
Online: www.lifescienceworld.com/2007/obesity
Email: caroline.thoresen@terrappinn.com
Post: Terrapinn Ltd, Wren House,
 43 Hatton Garden London, EC1N 8EL, UK

Yes, please register me for:

Package	Dates	Received before 13 September 2007	Received from 14 September to 18 October 2007	Received from 18 October 2007
<input type="checkbox"/> Gold pass – all 3 days	26 – 28 November 2007	£2,065.50 + VAT £361.46 = £2426.96 SAVE £269.67!	£2,180.25 + VAT £381.54 = £2,561.79 SAVE £134.84!	£2,295 + VAT £401.63 = £2,696.63
<input type="checkbox"/> 2 day conference	27 – 28 November 2007	£1,480.50 + VAT £259.09 = £1,739.59 SAVE £193.29!	£1,562.75 + VAT £273.48 = £1,836.23 SAVE £96.65!	£1,645 + VAT £287.88 = £1,932.88
<input type="checkbox"/> Pre-conference briefing	26 November 2007	£805.50 + VAT £140.96 = £946.46 SAVE £105.17!	£850.25 + VAT £148.79 = £999.04 SAVE £52.59!	£895 + VAT £156.63 = £1051.63

* Payment terms are 7 days. Registration fee includes lunch, refreshments and full conference documentation. The fee does not include hotel accommodation.

Register before 13 September and save up to £269.67!

Yes. I am a small biotech / spin-out company (research and development focus, in existence for 2 years or less and 50 employees or less), government, academia or non-profit organisation. I therefore qualify for a discount of 50% deducted from the original price.

The following discounted registration price is subject to Terrapinn approval

Package	Dates	50% discount price	Saving
<input type="checkbox"/> Gold pass – all 3 days	26 – 28 November 2007	£1,147.50 + VAT £200.81 = £1,348.31	SAVE £1348.32!
<input type="checkbox"/> 2 day conference	27 – 28 November 2007	£822.50 + VAT £143.94 = £966.44	SAVE £966.44!
<input type="checkbox"/> Pre-conference briefing	26 November 2007	£447.50 + VAT £78.31 = £525.81	SAVE £525.82!

**Discounted booking prices cannot be used in conjunction with any other promotional prices

Attendee details

	Mr/Mrs/Ms	Full name	Job title	Telephone	Email
1					
2					
3					
4					

For groups of more than 4 please attach a separate sheet with details of all attendees. Alternatively call +44 (0) 207 242 2324

Company details

Signatory must be authorised to sign on behalf of contracting organisation

Name:.....

Job title:.....

Authorising signature:.....

Email:.....

Organisation name:.....

Industry:.....

Address:.....

Postcode:..... Country:.....

Tel:..... Fax:.....

Method of payment

Payment terms are 7 days. The conference registration pack will be sent to you once payment has been received.

Bank Transfer Crossed cheque payable to Terrapinn Ltd
 Diners Club Visa American Express Mastercard

Card number:

Cardholder's signature:

Expiry date: Security code:

Bank Transfers: Account name: Terrapinn Limited, Sort code: 30-94-31, Bank Account Number: 0602538, Bank Name & Address: Lloyds TSB, 6 Holborn Circus, London EC1N 2HP, Swift Address: LOYDGB2L, IBAN: GB06 LOYD 3094 3100 6025 38, BIC: LOYDGB21037. **Reference: please quote 14/1327 and the delegate's name**

For official use only

Received: Date: Code 14/1327/A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Venue and hotel accommodation

Venue: Millennium Hotel London Mayfair, 44 Grosvenor Square, Mayfair London W1K 2HP, United Kingdom T: +44 (0) 207 629 9400 F: +44 (0) 207 629 7736 W: www.MillenniumHotels.co.uk/Mayfair

Hotel accommodation: The conference fee does not include accommodation. Terrapinn has obtained specially discounted rates for all attendees. A hotel booking form will be sent to all registered attendees. Please book your accommodation early to avoid disappointment.

Data Protection

Terrapinn (or its agents) may contact you by mail, phone or email about products and services offered by Terrapinn and its group companies, which Terrapinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Terrapinn may also disclose your contact details to such third parties to enable them to contact you directly. Certain entities to which Terrapinn discloses your contact details are located in territories overseas which have fewer legal safeguards to protect personal data. By returning this form to us, you agree to our processing of your personal information in this way. Please tick the appropriate box if you do not wish to receive such information from:

the Terrapinn group; or reputable third parties.

Cancellation

- Should you be unable to attend, a substitute delegate is welcome at no extra charge.
- Should you wish to cancel completely a charge of 50% of the registration fee, plus £150 (+ VAT) administrative charge will be made for cancellations received in writing at least 30 days prior to the conference start date.
- Alternatively, you may choose a credit note for the full value of the registration price (valid for 1 year), which may be put towards another Terrapinn event.
- The company regrets that no cancellations will be accepted within 30 days of the conference start date. Prepayments will not be refunded and invoiced sums will be payable in full, except in cases where it has been possible to mitigate loss.
- Course documentation will, however be made available to the delegate. Terrapinn reserves the right to alter the programme without notice.

Insert your voucher code

Code:.....